# A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

> **NCT00934089** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 31 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** PF-04217329
- **DRUG:** latanoprost vehicle
- **DRUG:** PF-04217329
- **DRUG:** latanoprost

## Key facts

- **NCT ID:** NCT00934089
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934089, "A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00934089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*